Supernus Pharmaceuticals | SUPN - Sales Revenues


Supernus Pharmaceuticals reported $207.71M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Abbott USD 11.16B 300M Mar/2026
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Canopy Growth CAD 74.54M 7.86M Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 164.9M 37.22M Mar/2026
Eisai JPY 205.43B 14.51B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Novo Nordisk DKK 96.82B 17.68B Mar/2026
Pacira USD 177M 19.87M Mar/2026
Perrigo USD 969M 141M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
Xeris Pharmaceuticals USD 83.13M 2.68M Mar/2026